Kamada (NASDAQ:KMDA), a vertical integrated biopharmaceutical company specializing in plasma-derived therapeutics, reported fourth-quarter and full-year 2025 financial results on Wednesday.
While the company maintained its streak of annual profitability, its quarterly performance came in below analyst projections as global distribution and supply chain timing impacted year-end deliveries.
For the quarter ended December 31, 2025, the Rehovot-based company reported a net profit of $3.6 million, or $0.06 per share.
This fell short of the $0.09 per share consensus estimate from analysts surveyed by Zacks Investment Research.
Revenue for the period totaled $44.7 million, slightly missing the $45.7 million forecasted by the Street.
Despite the quarterly disconnect, Kamada’s full-year 2025 performance underscored a period of significant scaling.
The company reported a total annual profit of $20.2 million, or $0.35 per share, on record revenue of $180.5 million.
The growth has been largely driven by the company’s diversified portfolio of IgG products and its proprietary Alpha-1 Antitrypsin (AAT) therapy, which continues to see steady demand in international markets.
Looking ahead, the company expects full-year revenue to land between $200 million and $205 million, representing a projected growth rate of approximately 11% to 14% over 2025 levels.